Chronic endothelial injury hypothesis

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Retrieved on: 
Wednesday, September 6, 2023
Sports, General Sports, Biotechnology, FDA, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Graft-versus-host disease, Investigational New Drug, HIE, Food and Drug Administration, Pharmacokinetics, Rodels-Realta railway station, Biomarker, Inflammation, Doctor of Philosophy, System, Chronic endothelial injury hypothesis, MD, Patient, Immune system, Neutrophil extracellular traps, IND, Food, Safety, Hypoxia (medical), Pharmaceutical industry

“In steroid-refractory patients, acute Graft-versus-Host Disease is driven by endothelial injury followed by neutrophil recruitment and activation, NETosis and complement activation.

Key Points: 
  • “In steroid-refractory patients, acute Graft-versus-Host Disease is driven by endothelial injury followed by neutrophil recruitment and activation, NETosis and complement activation.
  • This underlying pathogenesis has a devastating impact on patients with steroid-refractory acute GvHD and calls for innovative and effective treatments.
  • “This FDA clearance marks an important new milestone for ReAlta as we explore the potential of RLS-0071 across multiple indications."
  • The Phase 2 clinical trial will be an open label, prospective dose-ranging study with escalation and expansion cohorts to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, dosing and efficacy in hospitalized patients with steroid-refractory acute Graft-versus-Host Disease.

XORTX Sponsored American Society of Nephrology Study Abstract Available Online

Retrieved on: 
Tuesday, October 25, 2022
Chronic endothelial injury hypothesis, Growth, TSX Venture Exchange, Incidence, Kidney, Research, Society, News, Mouse, NASDAQ, Nephrology, GLOBE, Life, Coronavirus, American Society of Nephrology, DS, Therapy, Patient, Quality of life, Kidney disease, CEO, Analysis, Conference, SEC, Session, International, University, Health, Polycystic kidney disease, Diagnosis, PCK, Abstract, HIV disease progression rates, Human, Oxidase test, ASN, Fibrosis, COVID-19, Form, Nasdaq, PKD, Diabetic nephropathy, University of Colorado Denver School of Public Affairs, Allantoin, Association, No, Chronic pain, Unitary state, Hyperuricemia, Autosome, Uric acid, Cyst, Letter, OXO, Urate oxidase, Xanthine oxidase, Pharmaceutical industry, Gum arabic, ADPKD, Creatinine, Kidney stone disease

CALGARY, Alberta, Oct. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce online availability of the peer-reviewed abstract to be presented November 4, 2022 at the American Society of Nephrology (“ASN”) Annual Conference – Kidney Week. The abstract presents new discoveries in two species – mouse and rat models of polycystic kidney disease (“PKD”) and reports original work showing the harmful consequence of chronically increased uric acid on both structure and function of kidneys. The Abstract “Raising Serum Uric Acid with a Uricase Inhibitor Worsens PKD in Rat and Mouse models” will be presented during the Session Title: Genetic Diseases of the Kidneys, by Dr. Charles Edelstein of the University of Colorado and Dr. Allen Davidoff of XORTX. 

Key Points: 
  • The abstract presents the findings of studies conducted at the University of Colorado, by Dr. Charles Edelstein and the PKD research team.
  • The aim of this study was to determine whether raising serum uric acid with OXO was associated with worse PKD.
  • We anticipate a further updated information near the time that the abstract for the ASN becomes public.
  • At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients.

Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease

Retrieved on: 
Wednesday, August 31, 2022
Medical Devices, Health, Biometrics, Clinical Trials, Pharmaceutical, Biotechnology, Software, Inflammation, Patient, HRCT, Technology, Pharmacokinetics, SLP, Research, Solution, Glossary of biology, AAPS, LinkedIn, Biophysical environment, Risk, Systemic scleroderma, Chronic endothelial injury hypothesis, GGO, Economics, Prognosis, Simulations Plus, Scleroderma, ECM, U.S. Securities and Exchange Commission, RO, Mission statement, Fibrosis, Nasdaq, Company, HC, FDA, Biotechnology, Element, Population, Biomarker, ESG, Extracellular matrix, Drug discovery, Private Securities Litigation Reform Act, Drug development, QSP, ILD, DSS, Pharmaceutical industry, Medical device, Risk management

Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym version 1A, quantitative systems pharmacology (QSP) modeling software.

Key Points: 
  • Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released ILDsym version 1A, quantitative systems pharmacology (QSP) modeling software.
  • Dr. Lisl Shoda , associate vice president, added: Interstitial lung disease significantly worsens the prognosis for patients with SSc and increases their healthcare costs by roughly 50%.
  • ILDsym and our scientific consulting expertise are positioned to support our clients in the development of novel treatments for SScILD.
  • Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions.

New Replica Project Study Finds That Quitting Smoking With Low-Risk Products Can Restore The Vascular System

Retrieved on: 
Wednesday, July 27, 2022
Smoke, Arteriosclerosis, Molecular reference standards, Tobacco smoking, Harm reduction, University, GLOBE, Tobacco, Toxicity, Center, Chronic endothelial injury hypothesis, Blood, Laboratory, University of Catania, Smoking, Foundation, Endothelium, Research, Smokeless tobacco, Cardiovascular disease, Degenerative disease, Atherosclerosis, Risk, Herbal cigarette, Time-invariant system, Center of excellence, Cell, Pathology, Policy, Acceleration, Replica, Hypertension, Death, Many, Pharmaceutical industry

Endothelial damage represents the original pathological occurrence that leads to diseases such as arteriosclerosis and cigarette smoking is the initiator.

Key Points: 
  • Endothelial damage represents the original pathological occurrence that leads to diseases such as arteriosclerosis and cigarette smoking is the initiator.
  • Smoking compromises the normal activity of the endothelium, causing damage to the vascular system and leading to the development of pathologies such as hypertension and arteriosclerosis.
  • Cigarette smoking and the smoke toxicants are associated with impairment of repair mechanisms necessary for vascular endothelium homeostasis, such as the inhibition of endothelial cell migration.
  • Numerous international studies investigated the effects of cigarette smoking on endothelial cell migration and the related vascular damage: in particular, a study by Taylor et al.

Dietary Guidelines Report Right on Eating Plant-Based Diet, Avoiding Saturated Fat, Meat, Cholesterol

Retrieved on: 
Wednesday, July 15, 2020
Cardiology, Diabetes, Health, General Health, Women, Seniors, Food, Beverage, MEN, Retail, Fitness & Nutrition, Consumer, Nutrition, Health, Articles, Branches of biology, Diets, Cholestanes, Cholesterol, Saturated fat, Dietary Guidelines for Americans, Dairy product, Saturated fat and cardiovascular disease, Chronic endothelial injury hypothesis

But they missed the mark when they failed to warn against dairy products, which are the leading source of saturated fat in the American diet.

Key Points: 
  • But they missed the mark when they failed to warn against dairy products, which are the leading source of saturated fat in the American diet.
  • The U.S. Department of Agriculture and Department of Health and Human Services will use the DGACs report to develop the 2020-2025 Dietary Guidelines for Americans.
  • The key takeaways from the DGAC scientific report are:
    Cholesterol: The DGAC says its prudent to recommend lower intake of foods high in dietary cholesterol.
  • Research shows that dietary cholesterol raises blood cholesterol levels, raising the risk of heart disease and death.